The FDA has expanded the indication for afatinib (Gilotrif) to include the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have uncommon EGFR alterations in L861Q, G719X, and/or S768I. onclive.com/web-exclusives/... This FDA approval was based on trials studying the response to afatinib in patients whose tumors had mutations in EGFR. The results help advance our understanding of the efficacy of afatinib and also highlight the importance of tumor testing of patients with lung cancer.
News from the FDA: the indication for ... - Lung Cancer Support
News from the FDA: the indication for a drug targeting EGFR is expanded to uncommon mutations
Written by
MFH_Advocate
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
scifiknitterBlogger
More options are good news! This is based on a small subset of patients, but response rates and duration of efficacy were're both compelling.
Not what you're looking for?
You may also like...
First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer (stage IB-IIIA)
On December 18th, 2020, the Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for...
An immunotherapy now approved for first-line treatment
Late yesterday, the FDA approved Keytruda (an immunotherapy) as a first-line treatment for patients...
Opdivo and Yervoy combination approved for Non-small cell lung cancer
More exciting approval announcements for this week.
On May 15th, 2020, the Food and Drug...
FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
On May 18th, 2020, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the...
FDA approves another blood test for a mutation (T790M) in lung cancer
Some of you may have heard about new blood tests to check for lung cancer mutations. And you may...
FDA Approves Keytruda Combo for Lung Cancer
EGFR mutations on exon 20 and exon 21
Farewell to our dear friend Anita 
